KRAS and neoplasm: Additionally, CMS4 KRAS mutant tumours treated with cetuximab showed worse OS (Fig. 4d; p = 0.002, HR = 2.60 [1.44–4.70], FDRcet < 0.1) and PFS (Supplementary Fig. 13a, c).